Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer (EARLY HEART Study) in the Frame of the Implications of MEDIcal Low Dose RADiation Exposure (MEDIRAD) European Project
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 250
- 试验地点
- 5
- 主要终点
- Number of patients with decreased myocardial function assessed by echocardiography
研究概览
简要总结
Breast cancer (BC) radiotherapy leads to coincidental radiation of the heart, resulting in increased risk of a variety of heart diseases. Identifying BC patients with the highest risk of radiation-induced cardiac complications is crucial for developing strategies for primary and secondary prevention. Little has been done on the relationship between dose distribution to different anatomical cardiac structures during radiotherapy and early cardiovascular changes that may lead to cardiac complications.
In the framework of the European project MEDIRAD, the EARLY-HEART multicenter prospective cohort was launched in August 2017, involving 5 investigating centers from France, Netherlands, Germany, Spain and Portugal. With 250 BC patients prospectively followed for 2 years, the main objective is to identify and validate the most important cardiac imaging (echocardiography, computed tomography coronary angiography, cardiac magnetic resonance imaging) and circulating biomarkers of radiation-induced cardiovascular changes arising in the first 2 years after BC radiotherapy.
详细描述
EARLY-HEART is a multicentre prospective cohort study that will include 250 female primary breast cancer cases aged 40-75 years treated with postoperative radiotherapy (RT) alone after breast-conserving surgery using modern planning-CT based RT technologies and followed for 2 years after RT in one of the 5 participating hospitals. In addition to the standard follow-up, patients will need to give repeated blood samples and will undergo repeated cardiac imaging:
- Functional and anatomical cardiac imaging biomarkers will be based on automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed Tomography Coronary Angiography (CT) and cardiac magnetic resonance imaging (MRI).
- Circulating biomarkers (BLOOD) will be based on a panel of multiple classical or novel blood-based biomarkers.
Imaging and circulating biomarkers measurements will be assessed at baseline before RT (ECHO, CT, MRI, BLOOD); at the end of RT (BLOOD); 6 months after RT (ECHO, MRI, BLOOD) and 24 months after RT (ECHO, CT, MRI, BLOOD).
Changes in functional and anatomical cardiac imaging and circulating biomarkers between unexposed status before RT and exposed status after RT at different time points will be first analysed to evaluate the effects of RT on the heart.
All relevant DICOM-data (including planning-CT scans and the ECHO, MRI and CT) will be centralized to the MEDIRAD-ENACT database managed by University of Groningen for automated segmentation of all cardiac substructures (including coronary arteries) to ensure uniformity of the segmentation procedure between centres. The RT planning CTs will be used to generate dose volume histograms and 3D dose maps of the heart and cardiac substructures in order to correlate the localization of any cardiovascular change with the anatomical dose distribution.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Prevention
- 盲法
- None
入排标准
- 年龄范围
- 40 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Female unilateral breast cancer patients
- •Treated with primary breast conserving surgery for stage I-III invasive adenocarcinoma of the breast or ductal carcinoma in situ (DCIS)
- •Age between 40-75 years at time of start radiotherapy
- •World Health Organisation (WHO) performance status 0-1
- •Planned for radiotherapy alone to the breast with or without the lymph node areas
- •Radiotherapy based on planning-CT scan using either three dimensional conformal radiation therapy (3D-CRT), Intensity-modulated radiotherapy (IMRT), or Volumetric Arc Therapy (VMAT/RapidArc)
- •Written Informed consent
排除标准
- •Male breast cancer patients
- •Neoadjuvant or adjuvant chemotherapy
- •M1 disease (metastatic breast cancer)
- •Medical history of coronary artery disease and/or myocardial infarction and/or atrial fibrillation
- •Previous thoracic or mediastinal radiation
- •Contraindications to injection of iodinated contrast such as allergy or renal failure
- •Pregnancy or lactation
- •Atrial fibrillation detected during electrocardiogram before radiotherapy
- •Abnormal echocardiography before radiotherapy defined as: Left Ventricular Ejection Fraction<50%; longitudinal strain ≤ -16%; longitudinal strain rate <-1%, and/or abnormal wall motion
- •Presence of myocardial infarction detected during MRI before radiotherapy
- •CT or MRI results before radiotherapy requiring revascularisation
结局指标
主要结局
Number of patients with decreased myocardial function assessed by echocardiography
时间窗: 2 years after radiotherapy (baseline measurements performed before radiotherapy)
Number of patients with an increased of at least 2.5% in the Global Longitudinal Strain (GLS) between baseline and 2 years after radiotherapy
次要结局
- Changes in circulating biomarkers measurements(at the end of radiotherapy (through radiotherapy completion, an average of 5 weeks after starting date of radiotherapy), 6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy))
- Anatomical changes in coronary arteries assessed by cardiac CT(2 years after radiotherapy (baseline measurements performed before radiotherapy))
- Changes in myocardial function measurements assessed by echocardiography(6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy))
- Myocardial tissue abnormalities assessed by cardiac MRI(6 months and 2 years after radiotherapy (baseline measurements performed before radiotherapy))
研究者
Sophie JACOB
PhD
Institut de Radioprotection et de Surete Nucleaire